期刊
FRONTIERS IN IMMUNOLOGY
卷 13, 期 -, 页码 -出版社
FRONTIERS MEDIA SA
DOI: 10.3389/fimmu.2022.961805
关键词
immunotherapy; tumor microenvironment; immune checkpoint inhibitors; CAR-T; cancer vaccines
类别
资金
- Science and Technology Commission of Shanghai [18ZR1403900]
- National Natural Science Foundation of China [81872895]
- project on joint translational research in the School of Pharmacy and Minhang Hospital [RO-MY201712]
- Jinan Science and Technology Bureau, Innovation team for the development and evaluation of new drugs for oncology immunotherapy [2020GXRC041]
Immune checkpoint therapy utilizing PD-1 antibodies has demonstrated significant clinical value and therapeutic potential, although it is not without limitations such as immune-related adverse events, cytokine storm, and low response rates. This review discusses the basic classification, research progress, and limitations of cancer immunotherapy, as well as providing insights into the development of new anticancer immunotherapy strategies through the analysis of resistance mechanisms and combination therapy.
Immune checkpoint therapy via PD-1 antibodies has shown exciting clinical value and robust therapeutic potential in clinical practice. It can significantly improve progression-free survival and overall survival. Following surgery, radiotherapy, chemotherapy, and targeted therapy, cancer treatment has now entered the age of immunotherapy. Although cancer immunotherapy has shown remarkable efficacy, it also suffers from limitations such as irAEs, cytokine storm, low response rate, etc. In this review, we discuss the basic classification, research progress, and limitations of cancer immunotherapy. Besides, by combining cancer immunotherapy resistance mechanism with analysis of combination therapy, we give our insights into the development of new anticancer immunotherapy strategies.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据